Dementia

The Readout LOUD By Damian Garde and Meg Tirrell

Listen: The mRNA gold rush, Delta’s alarming rise, & the next treatment for Alzheimer’s

Pharmalot By Ed Silverman

Federal watchdog will review the controversial FDA approval of Biogen’s Alzheimer’s drug

Health By Andrew Joseph and Rachel Cohrs

Alzheimer’s patients are in limbo as hospitals, insurers grapple with whether to offer Aduhelm

dementia alzheimer's disease progression

Adam's Take By Adam Feuerstein

Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable

D.C. Diagnosis By Nicholas Florko

What happened to the FDA’s toughest regulator?

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: The FDA’s future, Biden’s tight ship, & the latest Aduhelm twist

Politics By Rachel Cohrs

The ins and outs of the rare, controversial way Medicare might pay for Biogen’s new Alzheimer’s drug

Politics By Rachel Cohrs

FDA chief Janet Woodcock acknowledges agency may have misstepped in process leading up to Alzheimer’s drug approval

Biotech By Jonathan Saltzman — Boston Globe

‘This is unprecedented’: Several private insurers won’t cover Biogen’s Alzheimer’s drug

D.C. Diagnosis By Nicholas Florko

Biden wants a drug pricing plan in 45 days. Who’s going to write it?

Politics By Rachel Cohrs and Ed Silverman

Medicare starts process that could limit access to Biogen’s new Alzheimer’s drug

Politics By Rachel Cohrs

Powerful House Democrats demand documents from Biogen about coordination with FDA on new Alzheimer’s drug

Exclusive By Nicholas Florko, Ed Silverman, Rachel Cohrs and Damian Garde

FDA’s expansive Alzheimer’s drug approval surprised even top agency officials

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Aduhelm’s latest twist, how Covid variants are shaping the summer, & a digital health boom

Politics By Nicholas Florko

Is the Alzheimer’s Association really pushing Biogen to lower its new drug’s price — or is it lip service?

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: A CRISPR milestone, Biogen’s FDA saga, & George Yancopoulos on biotech in 2021

Biotech By Damian Garde and Nicholas Florko

Calls grow for an investigation into FDA approval of Biogen’s Alzheimer’s drug

Politics By Rachel Cohrs and J. Emory Parker

Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?

Politics By Rachel Cohrs

House leaders to investigate FDA approval and price of Biogen’s Alzheimer’s drug

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: FDA inner workings, GSK’s foggy future, & the alarming rise in colorectal cancer

Politics By Nicholas Florko

FDA’s Woodcock is just ‘not that concerned’ about the criticism over Biogen’s Alzheimer’s drug, Aduhelm

Health By Megan Molteni

A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?

Politics By Nicholas Florko

Bipartisan pair of senators calls on Congress to examine expensive new Alzheimer’s drug

Politics By Rachel Cohrs

Biogen isn’t the only drug company that will profit from the new Alzheimer’s drug Aduhelm

Exclusive By Olivia Goldhill

Most Read

How Biogen found a believer: At the FDA, a hard-nosed regulator was won over on controversial Alzheimer’s drug

Here’s why simply approving Aduhelm can’t guarantee a golden age of Alzheimer’s R&D

Biogen mounts defense of its Alzheimer’s drug, saying ‘misinformation’ is fueling controversy

Inside ‘Project Onyx’: How Biogen used an FDA back channel to win approval of its polarizing Alzheimer’s drug

FDA calls for federal investigation into its controversial Alzheimer’s drug approval

Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say

6 ways the FDA’s approval of Aduhelm does more harm than good

Using human brain tissue in lab dishes, researchers show herpes link to Alzheimer’s

All Coverage

Listen: The mRNA gold rush, Delta’s alarming rise, & the next treatment for Alzheimer’s

Federal watchdog will review the controversial FDA approval of Biogen’s Alzheimer’s drug

Alzheimer’s patients are in limbo as hospitals, insurers grapple with whether to offer Aduhelm

Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable

What happened to the FDA’s toughest regulator?

Listen: The FDA’s future, Biden’s tight ship, & the latest Aduhelm twist

The ins and outs of the rare, controversial way Medicare might pay for Biogen’s new Alzheimer’s drug

FDA chief Janet Woodcock acknowledges agency may have misstepped in process leading up to Alzheimer’s drug approval

‘This is unprecedented’: Several private insurers won’t cover Biogen’s Alzheimer’s drug

Biden wants a drug pricing plan in 45 days. Who’s going to write it?

Medicare starts process that could limit access to Biogen’s new Alzheimer’s drug

Powerful House Democrats demand documents from Biogen about coordination with FDA on new Alzheimer’s drug

FDA’s expansive Alzheimer’s drug approval surprised even top agency officials

Listen: Aduhelm’s latest twist, how Covid variants are shaping the summer, & a digital health boom

Is the Alzheimer’s Association really pushing Biogen to lower its new drug’s price — or is it lip service?

Listen: A CRISPR milestone, Biogen’s FDA saga, & George Yancopoulos on biotech in 2021

Calls grow for an investigation into FDA approval of Biogen’s Alzheimer’s drug

Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?

House leaders to investigate FDA approval and price of Biogen’s Alzheimer’s drug

Listen: FDA inner workings, GSK’s foggy future, & the alarming rise in colorectal cancer

FDA’s Woodcock is just ‘not that concerned’ about the criticism over Biogen’s Alzheimer’s drug, Aduhelm

A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?

Bipartisan pair of senators calls on Congress to examine expensive new Alzheimer’s drug

Biogen isn’t the only drug company that will profit from the new Alzheimer’s drug Aduhelm

Athira Pharma CEO placed on leave amid allegations of altered images in her research papers

Most Read

All Coverage